The latest headlines across every section, pulled from official and open-access sources.
MRSA, MSSA, Gram-negative bacteraemia infections by organisation and location of onset, and Clostridioides difficile infections (CDI) by organisation and prior trust exposure.
Information on the expansion of the eligibility criteria of the older adults respiratory syncytial virus (RSV) vaccination programme from 1 September 2026.
List of those receiving pre-release access to the monthly UK Health Security Agency mandatory healthcare-associated infections (HCAI) statistical release.
Information to help schools support the delivery of the National Child Measurement Programme to measure children's height and weight in reception and year 6.
Guidance on running the National Child Measurement Programme, which collects the height and weight of reception and year 6 children across England every year.
Pacira BioSciences offloaded its cold-therapy pain relief device to medtech orthopedics specialist Zimmer Biomet in a deal valued at up to $140 million.
Ipsen is on a roll this week, scooping up its second biotech in three days in order to firm up its pipeline with promising clinical-stage candidates.
QuantumCell has licensed AlzeCure Pharma’s Alzheimer’s disease platform and lead asset for $12 million upfront, bagging a potentially symptom-relieving drug candidate that is on the cusp of phase 2.
Anthropic unveiled Claude Science, an AI workbench designed to run — not just assist with — pharma research. The company is seeking to build out its customer base in the pharma sector as it deepens its healthcare push ahead of a widely anticipated IPO. The post Anthropic Launches Claude Science to Court Pharma Ahead of IPO appeared first on MedCity News .
Diabetes and Endocrinology
This cross-sectional study describes trends in physicians, advanced practice registered nurses, and physician associates providing home-based medical care for Medicaid beneficiaries between 2018 and 2022.
This randomized clinical trial investigates the effect of cognitive rehabilitation on goal attainment, cognitive, and clinical outcomes in individuals with long COVID–related cognitive impairment.
This cohort study compares the outcomes associated with first-line enfortumab vedotin plus pembrolizumab and gemcitabine plus cisplatin among patients with metastatic urothelial carcinoma.
This cohort study combines data from 4 US epidemiological studies to examine contributions of clinical, lifestyle, and sociodemographic factors to mortality differences among females identifying as Asian ethnicities compared with non-Latina White females and whether associations vary by nativity.
This cross-sectional study examines the association of race and ethnicity, health insurance type, and socioeconomic disadvantage with differences in continuous glucose monitoring among adults and children with diabetes.
This cohort study uses electronic medical record data to compare short- and long-term health care utilization costs among patients with obesity and diabetes treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) vs those who underwent bariatric metabolic surgery.
This cross-sectional study evaluates the association between food insecurity and guideline-concordant colorectal, breast, and cervical cancer screening and assesses whether Supplemental Nutrition Assistance Program (SNAP) participation was associated with attenuation of screening disparities among food-insecure US adults.
Servier completed its acquisition of Day One Biopharmaceuticals and its buyout of Edgewise Therapeutics’ neuromuscular business is expected to close later this year. At the BIO International Convention, Servier’s top business development executive explained the rationale for these deals and how they fit the company’s overall strategy. The post Servier Executive: ‘We Are Not Looking for Blockbusters, We’re Looking for Innovative Science’ appeared first on MedCity News .
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies
Zelis has introduced an AI solution to help health insurers streamline the No Surprises Act’s Independent Dispute Resolution process. The post Zelis Unveils Solution to Tackle Payer IDR Challenges appeared first on MedCity News .
The U.S. Food and Drug Administration today approved TREGZI, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
January - March 2026 | New Safety Information or Potential Signals of Serious Risks Identified by the FDA Adverse Event Monitoring System (AEMS)
When Roche previewed the Axelios technology in February, a Jefferies analyst called the next-generation sequencing platform the “greatest credible competitive threat in years.”
TAVR and surgery demonstrated comparable and sustained valve durability in low-risk patients with symptomatic severe aortic stenosis (AS), with both approaches showing low and similar rates of structural valve deterioration (SVD), all-cause bioprosthetic valve failure (BVF) and reintervention through seven years...